Zhang, X., Lv, Y., Zhang, X., Ye, X., Yang, C., Wei, J., Zhou, D., Xie, W., Meng, H., Tong, H., Jin, J., Yu, W. (2025). Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study. Blood. https://doi.org/10.1182/blood-2025-3596